An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients

Autor: B.P.S. Assis, S.A. Araujo, D.C. Wanderley, Evaldo Nascimento, R. A. Fabreti-Oliveira, J. Oliveira, M.F. Lasmar

Publikováno v: Brazilian Journal of Medical and Biological Research
Brazilian Journal of Medical and Biological Research v.54 n.4 2021
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
Brazilian Journal of Medical and Biological Research, Volume: 54, Issue: 4, Article number: e9369, Published: 03 MAR 2021

Tacrolimus (TAC), a calcineurin inhibitor, and everolimus (EVL), an mTOR inhibitor, have been used as immunosuppressive (ISS) drugs in post-kidney transplantation therapy. The objective of this study was to compare the efficacy of EVL vs TAC in the I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b102ced978c7905876242da777c772df
https://pubmed.ncbi.nlm.nih.gov/33681893

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.